🔎 Trials Near Me

Akèy › Kansè nan tete › Montana › Billings

Etid klinik pou Kansè nan tete nan Billings, MT

10 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Billings (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Ap rekriteFaz 3
  • Intermountain Healthcare, Billings
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Billings Clinic Cancer Center, Billings
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Ap rekriteFaz 2
  • St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07007559

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Ap rekriteFaz 2
  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06797635

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

Ap rekriteFaz 1
  • St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute), Billings
Laj 18 a 55 · Fanm · Mizajou Sep 9, 2026 · NCT07310420

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Ap rekriteFaz 3
  • Billings Clinic Cancer Center, Billings
  • Saint Vincent Frontier Cancer Center, Billings
  • Intermountain Health West End Clinic, Billings
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Ap rekriteFaz 3
  • SCL Health - Cancer Centers of Montana, Billings
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2026 · NCT06757634

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Ap rekriteFaz 3
  • Billings Clinic Cancer Center, Billings
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Ap rekriteEtid obsèvasyon
  • Billings Clinic Cancer Center, Billings
  • Montana Cancer Consortium NCORP, Billings
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Ap rekriteEtid obsèvasyon
  • Massive Bio SYNERGY-AI site, Billings
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

Etid Kansè nan tete nan lòt vil

Lòt etid nan Billings

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.